A Comparative pH-Dissolution Profile Analysis of Selected Commercial Levothyroxine Formulations in Lebanon Using Anion-Exchange HPLC Method: Implication on Interchangeability.

IF 3 Q3 PHARMACOLOGY & PHARMACY
Advances in Pharmacological and Pharmaceutical Sciences Pub Date : 2025-09-03 eCollection Date: 2025-01-01 DOI:10.1155/adpp/8833028
Malak AlBathish, Azza Gazy, Marwa Al Jamal
{"title":"A Comparative pH-Dissolution Profile Analysis of Selected Commercial Levothyroxine Formulations in Lebanon Using Anion-Exchange HPLC Method: Implication on Interchangeability.","authors":"Malak AlBathish, Azza Gazy, Marwa Al Jamal","doi":"10.1155/adpp/8833028","DOIUrl":null,"url":null,"abstract":"<p><p>Hypothyroidism is a common endocrine disorder that requires medical intervention by the administration of hormone replacement therapy: levothyroxine-a drug recognized as a NTI drug. Generic levothyroxine formulations can be considered as an economic alternative; however, bioequivalence problem has been encountered between various available levothyroxine formulations; thus, generic substitution is considered controversial. Dissolution testing is often used to assess the bioequivalence. The dissolution of levothyroxine from four pharmaceutical formulations: Euthyrox (old and new formulations), Eltroxin, and generic levothyroxine Sandoz was studied using a sensitive anion-exchange HPLC method. Dissolution profiles were compared using model-dependent and model-independent approaches. Results showed that there is significant difference between the formulations confirmed by the similarity (<i>f</i> <sub>1</sub>) and dissimilarity (<i>f</i> <sub>2</sub>) factors. All formulations showed variable and pH-dependent dissolution behaviors where at pH 1.2, the highest dissolution (almost 100%) is achieved. The drug-release kinetics model for each formulation varied depending on the dissolution media; where no unique kinetic model can be used to describe the release of levothyroxine from the tablets. The revealed variations in the in vitro dissolution profiles of the four formulations could be due to excipient variability from one brand to another affecting oral absorption and bioavailability and may be the reason behind bioequivalence problems between various formulations.</p>","PeriodicalId":7369,"journal":{"name":"Advances in Pharmacological and Pharmaceutical Sciences","volume":"2025 ","pages":"8833028"},"PeriodicalIF":3.0000,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408602/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Pharmacological and Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/adpp/8833028","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Hypothyroidism is a common endocrine disorder that requires medical intervention by the administration of hormone replacement therapy: levothyroxine-a drug recognized as a NTI drug. Generic levothyroxine formulations can be considered as an economic alternative; however, bioequivalence problem has been encountered between various available levothyroxine formulations; thus, generic substitution is considered controversial. Dissolution testing is often used to assess the bioequivalence. The dissolution of levothyroxine from four pharmaceutical formulations: Euthyrox (old and new formulations), Eltroxin, and generic levothyroxine Sandoz was studied using a sensitive anion-exchange HPLC method. Dissolution profiles were compared using model-dependent and model-independent approaches. Results showed that there is significant difference between the formulations confirmed by the similarity (f 1) and dissimilarity (f 2) factors. All formulations showed variable and pH-dependent dissolution behaviors where at pH 1.2, the highest dissolution (almost 100%) is achieved. The drug-release kinetics model for each formulation varied depending on the dissolution media; where no unique kinetic model can be used to describe the release of levothyroxine from the tablets. The revealed variations in the in vitro dissolution profiles of the four formulations could be due to excipient variability from one brand to another affecting oral absorption and bioavailability and may be the reason behind bioequivalence problems between various formulations.

用阴离子交换高效液相色谱法对黎巴嫩市售左甲状腺素配方的ph -溶出度分析:对互换性的影响。
甲状腺功能减退是一种常见的内分泌失调,需要通过激素替代疗法进行医学干预:左甲状腺素——一种被认为是NTI药物的药物。通用左甲状腺素制剂可被视为一种经济替代方案;然而,各种左甲状腺素制剂之间存在生物等效性问题;因此,通用替代被认为是有争议的。溶出度试验常用于评价生物等效性。采用敏感的阴离子交换高效液相色谱法研究了Euthyrox(旧配方和新配方)、Eltroxin和Sandoz通用左甲状腺素四种制剂中左甲状腺素的溶出度。使用模型依赖和模型独立的方法比较溶解曲线。结果表明,相似因子(f1)和不相似因子(f2)所证实的配方之间存在显著差异。所有配方都表现出不同的和依赖于pH的溶解行为,其中在pH 1.2时,溶出率最高(几乎100%)。各制剂的药物释放动力学模型因溶出介质的不同而不同;没有独特的动力学模型可以用来描述左甲状腺素从片剂中的释放。这四种制剂的体外溶出度差异可能是由于不同品牌的赋形剂的差异影响了口服吸收和生物利用度,这可能是不同制剂之间存在生物等效性问题的原因。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.30
自引率
3.60%
发文量
0
审稿时长
17 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信